5 Sickle Cell Therapies to Watch Following Pfizer’s Oxbryta Exit

In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.